Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Collaboration › Details

Moderna–Barclays: investor conference, 201903 supply service Moderna presents at Barclays Global Healthcare Conference in Miami


Period Period 2019-03-14
Region Region Miami, FL
  Country United States (USA)
Organisations Partner, 1st Moderna Therapeutics Inc.
  Today Moderna Inc. (Nasdaq: MRNA)
  Group Moderna (Group)
  Partner, 2nd Barclays (Group)
Product Product Barclays Global Healthcare Conference 2019 Miami
Persons Person Kim, Lorence H. (Moderna 201903 CFO)
  Person 2 Glashow, Jason (Moderna 201903 Head Corporate Communications)

Moderna, Inc.. (3/4/19). "Press Release: Moderna to Present at Upcoming Investor Conferences in March". Cambridge, MA.

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences:

> Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March 11, 2019 at 2:50 p.m. ET.

> Barclays Global Healthcare Conference 2019 in Miami on Thursday, March 14, 2019 at 8:30 a.m. ET.

> Oppenheimer 29th Annual Healthcare Conference in New York on Tuesday, March 19, 2019 at 8:35 a.m. ET.

A live webcast of each presentation will be available under “Events & Presentations” in the Investors section of the Moderna website at A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past four years. To learn more, visit

View source version on

Source: Moderna, Inc.

Moderna Contacts:

Lorence Kim
Chief Financial Officer

Jason Glashow
Head, Corporate Communications

Record changed: 2019-03-17


Picture [LSE] – The Business Web Portal 650x65px

More documents for Moderna (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top